About Creatine kinase U-type, mitochondrial
Creatine kinase U-type, mitochondrial (CKMT1A) is a protein
from Homo sapiens identified by UniProt accession
P12532, 417 residues long.
MolForge cross-references it against 0 known binders and
64 disease associations.
Target properties
| Protein name | Creatine kinase U-type, mitochondrial |
| UniProt accession | P12532 |
| Gene | CKMT1A |
| Organism | Homo sapiens |
| Length | 417 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (64)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.54
- Parkinson disease · score 0.31
- multiple sclerosis · score 0.31
- Alzheimer disease · score 0.31
- lysosomal storage disease · score 0.31
- neuroinflammatory disorder · score 0.24
- neoplasm · score 0.07
- cancer · score 0.07
- mean corpuscular hemoglobin concentration · score 0.05
- lymphocyte count · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P12532-F1 | alphafold | PREDICTED | 89.29 | — |
Amino-acid sequence (417 residues)
MAGPFSRLLS ARPGLRLLAL AGAGSLAAGF LLRPEPVRAA SERRRLYPPS AEYPDLRKHN NCMASHLTPA VYARLCDKTT PTGWTLDQCI QTGVDNPGHP FIKTVGMVAG DEETYEVFAD LFDPVIQERH NGYDPRTMKH TTDLDASKIR SGYFDERYVL SSRVRTGRSI RGLSLPPACT RAERREVERV VVDALSGLKG DLAGRYYRLS EMTEAEQQQL IDDHFLFDKP VSPLLTAAGM ARDWPDARGI WHNNEKSFLI WVNEEDHTRV ISMEKGGNMK RVFERFCRGL KEVERLIQER GWEFMWNERL GYILTCPSNL GTGLRAGVHI KLPLLSKDSR FPKILENLRL QKRGTGGVDT AATGGVFDIS NLDRLGKSEV ELVQLVIDGV NYLIDCERRL ERGQDIRIPT PVIHTKH
Explore Creatine kinase U-type, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets